Gerber M A, Shapiro E D, Burke G S, Parcells V J, Bell G L
Department of Pediatrics, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT 06106, USA.
N Engl J Med. 1996 Oct 24;335(17):1270-4. doi: 10.1056/NEJM199610243351703.
Although the incidence of Lyme disease is highest in children, there are few prospective data on the clinical manifestations and outcomes in children.
We conducted a prospective, longitudinal, community-based cohort study of children with newly diagnosed Lyme disease in an area of Connecticut in which the disease is highly endemic. We obtained clinical and demographic information and performed serial antibody tests and follow-up evaluations.
Over a period of 20 months, 201 consecutive patients were enrolled; their median age was 7 years (range, 1 to 21). The initial clinical manifestations of Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 percent, facial-nerve palsy in 3 percent, aseptic meningitis in 2 percent, and carditis in 0.5 percent. At presentation, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia burgdorferi. All but 3 of the 201 patients were treated for two to four weeks with conventional antimicrobial therapy, which was administered orally in 96 percent. All had prompt clinical responses. After four weeks, 94 percent were completely asymptomatic (including the two patients whose parents had refused to allow antimicrobial treatment). At follow-up a mean of 25.4 months later, none of the patients had evidence of either chronic or recurrent Lyme disease. Six patients subsequently had a new episode of erythema migrans.
About 90 percent of children with Lyme disease present with erythema migrans, which is an early stage of the disease. The prognosis is excellent for those with early Lyme disease who are treated promptly with conventional courses of antimicrobial agents.
尽管莱姆病在儿童中的发病率最高,但关于儿童临床表现及预后的前瞻性数据却很少。
我们在康涅狄格州一个莱姆病高度流行的地区,对新诊断为莱姆病的儿童进行了一项前瞻性、纵向、基于社区的队列研究。我们获取了临床和人口统计学信息,并进行了系列抗体检测及随访评估。
在20个月的时间里,连续纳入了201例患者;他们的中位年龄为7岁(范围为1至21岁)。莱姆病的初始临床表现为,66%的患者出现单个游走性红斑病变,23%出现多个游走性红斑病变,6%有关节炎,3%有面神经麻痹,2%有无菌性脑膜炎,0.5%有心脏炎。就诊时,单个游走性红斑病变的患者中有37%、多个游走性红斑病变的患者中有89%体内有抗伯氏疏螺旋体抗体。201例患者中除3例之外,其余均接受了两至四周的常规抗菌治疗,其中96%为口服给药。所有患者临床反应迅速。四周后,94%的患者完全无症状(包括两名家长拒绝给予抗菌治疗的患者)。在平均25.4个月后的随访中,没有患者有慢性或复发性莱姆病的证据。6例患者随后出现了新的游走性红斑发作。
约90%的莱姆病患儿表现为游走性红斑,这是该病的早期阶段。对于早期莱姆病患儿,及时采用常规疗程的抗菌药物治疗,预后极佳。